BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
IRVINE, Calif., April 03, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (Nasdaq:SCYX). Investors who purchased shares (1) pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company’s Initial Public Offering on or about May 2, 2014 and/or (2) between May 2, 2014 and March 2, 2017 inclusive (the “Class Period”), are encouraged to contact the Firm before the May 8, 2017 lead plaintiff motion deadline.
If you purchased shares of SCYNEXIS during the IPO or Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint alleges that during the Class Period, SCYNEXIS made false and/or misleading statements and/or failed to disclose: that the Company’s lead product, SCY-078, posed substantial undisclosed health and safety risks; that SCYNEXIS overstated the drug’s approval prospects and/or commercial viability; and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On March 2, 2017, SCYNEXIS announced that the U.S. Food and Drug Administration “informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data” of the formulation. The hold stems from “three mild-to-moderate thrombotic events in healthy volunteers” receiving the formulation. When this information was released to the public, shares of SCYNEXIS fell in value, thus harming investors.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contacts Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
